Business, energy, technology, markets and global industry news from Business News Today

MF59

PharmaDeviceNews MF59
Seasonal influenza vaccine research advances as CSL Seqirus reports Phase 3 data from a 7,699-participant study supporting its enhanced flu vaccine strategy, while mixed A/H3N2 results highlight the challenges of broad influenza strain protection. Representative image.
Pharma & Biotech

CSL Seqirus Phase 3 influenza vaccine study tests triple-enhancement strategy in older adults

CSL Seqirus’ 7,699-person Phase 3 study supports its enhanced flu-vaccine strategy, though one A/H3N2 comparison missed non-inferiority.

Read More